Ongoing Projects

The aim of the project is to develop a novel treatment for Malignant Mesothelioma, a rare, aggresive and poorly responsive cancer directly related to asbestos exposure. General objective pursued by the project include to conduct non-regulatory preclinical studies requested to conduct a clinical trial in patients.

(Co-financed by the Horizon 2020 Programme of the European Union)

METACAN aims to gaining understanding on how modulating cell metabolism may interfere with tumor growth focusing  as well in terms of the interactions between cancer and immune cells. The knowledge acquired will serve as a platform for drug discovery and diagnostics efforts that aim to therapeutically target metabolism, inflammation or immune responses for the treatment of a variety of cancers.

(Co-financed by the Horizon 2020 Programme of the European Union)

AMMIC project focuses on the implementation of a drug discovery and development platform, from early stages up to clinical trials, to accelerate the discovery of medicines for rare disease (the so called orphan drugs). Other aspects like genomics, epigenomics, transcriptomics and liquid biopsies are also addressed inside the project, in order to improve as well the diagnosis and managment of rare diseases, with a particular focus on pediatric oncology conditions.

(Co-financed by FEDER  programme)